Article thumbnail

Anti-angiogenesis therapies: their potential in cancer management

By Andrew Eichholz, Shairoz Merchant and Andrew M Gaya

Abstract

Angiogenesis plays an important role in normal animal growth and development. This process is also vital for the growth of tumors. Angiogenesis inhibitors have a different mechanism of action to traditional chemotherapy agents and radiation therapy. The angiogenesis inhibitors can act synergistically with conventional treatments and tend to have non-overlapping toxicities. There are four drugs which have a proven role in treating cancer patients. Bevacizumab is a humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF). Sunitinib and sorafenib inhibit multiple tyrosine kinase receptors that are important for angiogenesis. Thalidomide inhibits the activity of basic fibroblast growth factor-2 (bFGF). The licensed indications and the supporting evidence are discussed. Other drugs are currently being tested in clinical trials and the most promising of these drugs are discussed. Aflibercept, also known as VEGF-trap, is a recombinant fusion protein that binds to circulating VEGF. The vascular disrupting agents act by targeting established blood vessels. These exciting new treatments have the potential to transform the management of cancer

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2895781
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. 3rd. Vascular disrupting agents.
  2. (2002). A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res.
  3. A Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer.
  4. (2008). A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol.
  5. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon:
  6. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.
  7. A review and update of the current status of the vasculature-disabling agent combretastatinA4 phosphate (CA4P). Expert Opin Investig Drugs.
  8. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol.
  9. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
  10. (2009). Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther.
  11. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release.
  12. An overview of small-molecule inhibitors of VEGFR signaling.
  13. (1999). Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res.
  14. (2008). B017704 (AVAIL): A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients with advanced or recurrent non-squamous, non-small cell lung cancer. Ann Oncol.
  15. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.
  16. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
  17. (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol.
  18. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
  19. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
  20. (1996). Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.
  21. (2008). CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Paper presented at: ASCO Genitourinary Cancers Symposium
  22. (2007). CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res.
  23. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
  24. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.
  25. (1999). Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res.
  26. (2008). double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol.
  27. (2008). Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res.
  28. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
  29. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
  30. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
  31. (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev.
  32. (2007). Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol (Meeting Abstracts).
  33. (2007). Food and Drug Administration.
  34. (2008). Fosbretabulin (combretastatin A-4 phosphate [CA4P]) carboplatin and paclitaxel is active in patients with platinum resistant ovarian cancer [abstract 315]. International Gynecologic Cancer Society Meeting;
  35. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii35–ii38.
  36. Gastrointestinal stromal tumours: an update.
  37. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
  38. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res.
  39. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.
  40. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
  41. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
  42. Institute. FDA Approval for Bevacizumab.
  43. (2009). Institute. FDA Approval for Sorafenib Tosylate.
  44. (2009). Institutes of Health. A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer
  45. (2009). Institutes of Health. A study of alibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL). http://clinicaltrials.gov/ct2/show/ NCT00532155.
  46. (2009). Institutes of Health. A study of Avastin (bevacizumab) in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. http://clinicaltrials.gov/ct2/show/ NCT00943826.
  47. Institutes of Health. A study to assess the effectiveness of the combination of carboplatin, paclitaxel, bevacizumab and combretastatin (CA4P) in patients with chemotherapy naïve lung cancer. http://clinicaltrials.gov/ct2/show/NCT00653939. Accessed
  48. (2009). Institutes of Health. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE).
  49. (2009). Institutes of Health. Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR).
  50. (2009). Institutes of Health. BEATRICE study: A study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer. http:// clinicaltrials.gov/ct2/show/NCT00528567.
  51. (2009). Institutes of Health. BETH Study: Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab. http://clinicaltrials.
  52. (2009). Institutes of Health. Bevacizumab and combination chemotherapy in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes.
  53. (2009). Institutes of Health. Combination chemotherapy with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer. http://clinicaltrials.gov/ct2/show/ NCT00112918.
  54. Institutes of Health. Fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer.
  55. (2009). Institutes of Health. Oxaliplatin, leucovorin, and fluorouracil with and without bevacizumab in treating patients who have undergone surgery for stage II colon cancer. http://clinicaltrials.gov/ ct2/show/NCT00217737.
  56. (2009). Institutes of Health. Safety study of increasing doses of combretastatin in combination with bevacizumab (Avastin) in patients with advanced solid tumors. http://clinicaltrials.gov/ct2/show/ NCT00395434.
  57. (2009). Institutes of Health. Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. http:// clinicaltrials.gov/ct2/show/NCT00326898. Accessed
  58. (2009). Institutes of Health. Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. http://clinicaltrials.gov/ct2/show/ NCT00884741.
  59. (2009). Institutes of Health. Topotecan with or without aflibercept in treating patients with extensive-stage small cell lung cancer. http:// clinicaltrials.gov/ct2/show/NCT00828139.
  60. (2001). Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol.
  61. (1999). Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol.
  62. Limited. Summary of product characteristics: Avastin 25 mg/ml concentrate for solution for infusion. http://emc.medicines.org.uk/document.aspx?documentId=15748. Accessed
  63. (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res.
  64. Mechanisms of angiogenesis and arteriogenesis.
  65. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reducedintensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
  66. Molecular regulation of vessel maturation.
  67. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
  68. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol. (Meeting Abstracts). 2008;26(May 20 Suppl): abstr 10524.
  69. (2009). Oncology Clinical Trials Office (University of Oxford). A multicentre international study of capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer. http://www.octo-oxford.org.uk/alltrials/ trials/q2.html.
  70. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
  71. (1999). Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol.
  72. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
  73. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
  74. PDGFRA activating mutations in gastrointestinal stromal tumors.
  75. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
  76. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
  77. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
  78. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
  79. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
  80. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
  81. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
  82. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
  83. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
  84. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
  85. randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
  86. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39.
  87. (2009). RIBBON-1: Randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol.
  88. (2006). Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol. (Meeting Abstracts).
  89. Sorafenib in advanced clear-cell renal-cell carcinoma.
  90. Sorafenib in advanced hepatocellular carcinoma.
  91. (2009). Summary of product characteristics: Nexavar 200 mg film-coated tablets.
  92. (2009). Summary of product characteristics: Thalidomide Pharmion 50 mg Hard Capsules.
  93. Sunitinib in patients with metastatic renal cell carcinoma.
  94. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
  95. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
  96. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
  97. Thalidomide is an inhibitor of angiogenesis.
  98. (1996). Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.
  99. The first international conference on vascular targeting: meeting overview. Cancer Res.
  100. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
  101. Vascular disrupting agents: a new class of drug in cancer therapy.
  102. Vascular-specific growth factors and blood vessel formation.
  103. VEGF-Trap: a VEGF blocker with potent antitumor effects.